downloadthepersuaderesultsslideset-europatrial.pptVIP

ACE inhibitor therapy of proven benefit in secondary prevention in myocardial infarction and heart failure EUROPA concluded that perindopril was also beneficial in patients with CAD, without heart failure and with broad range of risk Within the coronary disease population, diabetics are a subpopulation at high risk Background Aim of the study To investigate the effect of the ACE inhibitorperindopril 8 mg once daily added to standard therapy on cardiovascular events in diabetic patients with documented coronary disease EUROPA is the only study to examine the effect of an ACE inhi